The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women

• Published in: Archives of gynecology and obstetrics 2012-11, Vol.286 (5), p.1233-1239
• Main Authors: Karakus, Mesut, Gelisgen, Remise, Topcuoglu, Ata, Guralp, Onur, Topcuoglu, Deniz, Simsek, Gonul, Uludag, Seyfettin, Uzun, Hafize
• Format: Article
• Language: English
• Subjects: Adiponectin - blood; Adiposity - drug effects; Adult; Androstenes - pharmacology; Blood Glucose - metabolism; Body Mass Index; Body measurements; Drug Therapy, Combination; Endocrinology; Estradiol - pharmacology; Estrogen Replacement Therapy; Estrogens - pharmacology; Female; General Gynecology; Ghrelin - blood; Glucagon-Like Peptide 1 - blood; Gynecology; Health risk assessment; Hormone replacement therapy; Human Genetics; Humans; Insulin - blood; Intracellular Signaling Peptides and Proteins - blood; Leptin - blood; Lipoproteins, HDL - blood; Lipoproteins, LDL - blood; Medicine; Medicine & Public Health; Middle Aged; Mineralocorticoid Receptor Antagonists - pharmacology; Neuropeptides - blood; Obstetrics/Perinatology/Midwifery; Orexins; Postmenopause - blood; Postmenopause - physiology; Premenopause - blood; Premenopause - physiology; Triglycerides - blood; Waist-Hip Ratio
• ISSN: 0932-0067; 1432-0711
• DOI: 10.1007/s00404-012-2437-9

Purpose To assess whether there are changes on anthropometric and biochemical measures of adiposity in pre- and postmenopausal women and in the latter before and after 6 months treatment with 17β-estradiol plus drospirenone. Methods Twenty postmenopausal and 20 premenopausal women were enrolled in a prospective comparative study. Postmenopausal women received 1 mg 17β-estradiol plus 2 mg drospirenone daily for 6 months. Measurements of body mass index (BMI), waist/hip ratio and plasmatic levels of insulin, glucose, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, leptin, adiponectin, orexin-A, glucagon-like peptide-1 (GLP-1) and ghrelin were performed in premenopausal (group 1) and postmenopausal women and in the latter before (group 2a) and after (group 2b) 6 months treatment with 17β-estradiol plus drospirenone. Results No significant changes in BMIs, insulin and glucose were observed between group 1 and 2a; and group 2a and 2b. GLP-1 levels were significantly increased in group 1 compared to group 2a ( p  = 0.035). Leptin levels were significantly increased ( p  = 0.001) and GLP-1 levels were significantly decreased ( p  = 0.021) in group 2b compared to group 2a. HDL was significantly decreased while LDL and triglyceride levels were significantly increased in group 2a compared to group 1. ( p  = 0.030, p  = 0.001, p  = 0.020; respectively) LDL was significantly decreased ( p  = 0.010) in group 2b compared to group 2a. GLP-1 had a positive correlation with orexin-A ( p